Recipharm, a Swedish CDMO, said the new blow-fill-seal equipment that was part of the company’s $22.3 million (€18 million) investment at its Kaysersberg, France, facility is now operational.
The project added a new blow-fill-seal high-speed filling and packaging line, giving the facility a total of eight lines and increasing the plant’s manufacturing capacity by 200 million unidoses a year.
The plant manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications.
The construction project added 2,400 square meters to the facility, providing room for three machines that will eventually let Recipharm produce more than 1.2 billion unidoses a year.
“We have worked hard to develop a flexible service that can cater for even the most complex of projects,” Yves Buelens, general manager of the plant, said in a statement. “Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”
Recipharm acquired the facility from Novartis’ Alcon unit for $19.7 million in 2015.